Medication-assisted treatment (MAT) for opioid use disorder should be available to patients regardless of their treatment setting, but most patients who are admitted to a residential level of care are not offered even one medication for OUD.
This webinar describes ways that patients in residential substance use treatment programs may be able to receive FDA-approved medications that are scientifically proven to save lives and promote recovery.
It outlines a) MAT basics, b) ways that outpatient MAT providers can partner with residential facilities and c) considerations for residential treatment providers in implementing MAT on-site.
Zac Talbott, MSW is the Chief Clinical Officer of ReVIDA Recovery Centers, a Tennessee-based company that operates office-based opioid treatment programs across multiple states. He is the President of NAMA Recovery and President of the Alcohol and Drug Abuse Certification Board of Georgia. He also serves on the Executive Committee of the Board of Directors of the Opioid Treatment Providers of Georgia, which is the Georgia opioid treatment providers association and state chapter of the American Association for the Treatment of Opioid Dependence. In addition, Zac serves as a Planning Partner for the Substance Abuse and Mental Health Services Administration.
Zac has provided operational, policy, compliance, and clinical consulting for office-based opioid treatment providers and opioid treatment programs across six U.S. states, and is proficient in the behavioral health accreditation standards of The Joint Commission and CARF International.